Articles On Cynata Therapeutics (ASX:CYP)

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Cynata Therapeutics has taken a vital step to conducting a clinical trial on its Cymerus product used to treat diabetic foot ulcers, as it looks to enter a market that could be worth US$10 billion by 2027.

SYDNEY, Oct. 16, 2021 /PRNewswire/ — Ensuring healthy lives and promoting physical and mental well-being is essential to sustainable development. Currently, the world is facing a global health crisis unlike any other. Global health has i...

Clinical-stage biotechnology company, Cynata Therapeutics has received a regulatory tick of approval to continue unchanged its ‘MEND’ clinical trial which is evaluating the company’s proprietary mesenchymal stem cell product in treating pat...

The ASX had a positive end to the week with the ASX 200 gaining 0.87% today taking its weekly gain to 1.9%. All sectors gained with the best being resources which gained nearly 1.7%. Australia’s rise was in line with the broader Asia-Pacifi...

The ASX 200 health stocks index (XHJ) had risen by 0.30% at the time of writing, compared to the broader ASX 200 index which is up by 0.74%. Immuron (ASX:IMC) jumped 19% this morning, after announcing a recent publication of the potential a...

Key highlights Cynata and Fujifilm have entered into a new strategic partnership which includes detailed and agreed core terms for Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata’s Cymerus the...

Biotechnology company Cynata Therapeutics has sealed a partnership agreement with Fujifilm as it moves towards a commercial manufacturing deal for its proprietary Cymerus stem cell therapy products and eyes an accelerated push into the all-...

Biotechnology company Cynata Therapeutics has received high-level coverage of its work on stem cell therapies for heart attacks with a well-known peer-reviewed scientific journal highlighting the successful trial use of its trademark Cymeru...

Cell therapy company Cynata Therapeutics (ASX:CYP) has announced that a scientific paper describing the use of its Cymerus mesenchymal stem cells in a model of myocardial infarction has been published in the peer-reviewed journal Cy...

ASX-listed clinical-stage biotechnology group Cynata Therapeutics is set to notch up yet another patent for its proprietary Cymerus mesenchymal stem cells technology. The company says it has now received the nod from the Patent Office of th...

ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)...

ShareCafeCell based therapeutic product platform Dr Ross Macdonald – Managing Director and Chief Executive Officer – Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeut...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

ASX-listed clinical-stage stem cell and regenerative medicine group Cynata Therapeutics’ proprietary Cymerus mesenchymal stem cells technology has been impressing the patent overseers in North America as the company looks set to secure yet...

Clinical-stage stem cell and regenerative medicine group Cynata Therapeutics looks to be on the verge of landing a prized patent from the US for its proprietary Cymerus mesenchymal stem cells technology. The company says it expects to recei...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Cynata Therapeutics has secured relevant ethics approval for a clinical trial on its Cymerus product for the treatment of diabetic foot ulcers as it looks to enter a market that could be worth US$10 billion within a decade.

Cynata Therapeutics has appointed leading clinical research organisation Dataphram Australia to manage and assist in an upcoming clinical trial for its Cymerus product for treating foot ulcers as it looks to enter a market that could be wor...

Summary The S&P/ASX 200 dropped 7.70 points or 0.11% to 7,300 by afternoon. The market sentiments were dented by coronavirus lockdowns and increased restrictions.  Redbubble was the top percentage gainer, while Gold Road Resources...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacem...

Escrow Watch is Stockhead’s monthly recap of the ASX companies that are releasing shares currently in escrow (also known as restricted securities) over the coming weeks. ASX shares in escrow are “locked away” and not listed on the bourse so...

Cynata Therapeutics has nailed an exclusive global licence agreement with TekCyte, a leading developer and manufacturer of thin-film polymer coatings, as it looks to conduct a clinical trial for the treatment of diabetic foot ulcers using T...

Summary The ASX 200 continued gaining momentum on Thursday, hitting a fresh record high. The market sentiment got a lift after trade balance and retail sales both rose in April. Energy stocks emerge as top gainers, owing to a rise in...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

ASX-listed clinical-stage stem cell and regenerative medicine group, Cynata Therapeutics has enrolled the first patient suffering from respiratory failure for a clinical trial that it has called “MEND” testing its proprietary Cymerus mesenc...

Summary Frontier Resources has successfully completed its landowner MRA Warden’s hearing as part of the renewal process of its wholly owned tenement. Vection Technologies has achieved a milestone of completing its first public hospital...

Summary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains in heavyweight healthcare and energy stocks. Retail player Kogan.Com and gold miner Silver Lake Resources are top performing stocks on the...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

ASX-listed clinical-stage stem cell and regenerative medicine group, Cynata Therapeutics is looking for patients who are suffering from osteoarthritis in the knees and severe respiratory distress for two separate clinical trials currently u...

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The health...

Cynata Therapeutics has received ethics committee approval to expand the recruitment criteria of its active “MEND” clinical trial in patients in intensive care with respiratory failure. The trial will now look beyond just patients suffering...

Source:Cryptographer, Shutterstock Summary Stem cell and regenerative medicine player Cynata Therapeutics will expand recruitment criteria for its active MEseNchymal coviD-19 clinical trial. Oventus medical enters into a virtual Lab i...

Stem cell therapeutics company Cynata's (ASX: CYP) pool of eligible patients in a COVID-19 treatment trial will be increased after the company received ethics committee approval to include those suffering from respiratory failure. The exp...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

2021 is set to be another big year for ASX capital raisings with solid volumes so far in 2021. In the first nine weeks of the new year, ASX companies have raised over $1.96 billion. Although this is lower than the $3 billion raised in the f...

Source: Guschenkova, Shutterstock Summary Medical technology player Nova Eye Medical announced the publication of positive patient follow-up data from a sub-study analysis of the LEAD trial. Cynata Therapeutics has initiated a new stu...

Having already successfully demonstrated the efficacy and safety of its proprietary stem cells on rodents with lung disease, Cynata Therapeutics is now set to embark on a new study on mice designed to find out how and why its stem cells wor...

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has announced the initiation of a new study to investigate its Cymerus mesenchymal stem cells. 

Cynata Therapeutics has signed an MoU with TekCyte Pty Ltd to access its wound dressing technology in the hope of commercialising TekCyte’s proprietary surface modifications of polymer-coated dressings for the delivery of Cynata’s mesenchym...

COVID-19 vaccines have reached Australia but ASX stocks that were making anti-COVID 19 drugs or tests are pushing on. The outbreak of the pandemic caused a number of ASX companies (big and small) to pivot to fighting COVID-19. In the last f...

Cynata Therapeutics’ recent run of successful capital raisings has been bolstered by a lazy $1.39m tax refund courtesy of the Federal Government’s Research & Development Tax Incentive grant scheme, adding to its already burgeoning $24.9...